ExeVir wins backing to develop llama-derived antibodies for COVID-19

By The Science Advisory Board staff writers

July 28, 2020 -- Belgian firm ExeVir Bio has closed on a 23-million euro ($26.9 million U.S.) series A financing round to support the development of its llama-derived antibody (VHH) technology in treating COVID-19.

The financing was led by Fund+, with the participation of Belgian life science research institute Vlaams Instituut voor Biotechnologie (VIB), UCB Ventures, the Belgian Federal Government via Société Fédérale de Participations et d'Investissement-Société Fédérale de Participations (SFPI-FPIM), V-Bio Ventures, and several Belgian family offices, according to ExeVir Bio. The company will use the funds to advance the antibody into clinical trials.

A spinoff of VIB, ExeVir Bio is utilizing its VHH technology to develop treatments for viral infections. Its lead asset, VHH782-Fc, binds to a unique epitope that is conserved in both SARS-CoV and SARS-CoV-2, preventing these viruses from entering the cell, according to the firm. As a result, it could be used as a therapeutic and a prophylactic.

Grifols delivers COVID-19 immunotherapy for clinical trials
Grifols has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, which will be conducted this summer.
SARS-CoV-2 envelope protein identified as target for antiviral drugs
Comparison of the SARS-CoV-2 genome with other betacoronaviruses can provide useful information on how drugs targeting other coronaviruses may improve...
Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately...
Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...
Immunic begins phase II trial of COVID-19 immunotherapy
Immunic has enrolled the first patients in a phase II clinical trial of IMU-838, a selective oral dihydroorotate dehydrogenase inhibitor, in combination...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter